[Russian study of efficacy and safety of an angiotensin converting enzyme inhibitor quinapril in patients with hypertension].
Efficacy and safety of an angiotensin converting enzyme inhibitor quinapril were assessed in a 12 week study on 258 patients with 1-2 degree hypertension and various concomitant pathology. The use of quinapril as monotherapy (10-40 mg/day) or in combination with hydrochlorothiazide (12.5 mg/day) was associated with blood pressure (BP) normalization (<140/90 mm Hg) or more then 10% BP lowering in 88% of patients. In the end of the study average blood pressure was 134/84 mm HG. Quinapril was well tolerated. These results allow to recommend the scheme of quinapril use utilized in the study for wide application for the treatment of outpatients with hypertension.